Sun Sentinel Broward Edition

Moderna creating ways to attack coronaviru­s variants, chairman says

- By Cindy Krischer Goodman

MIAMI — One of the biggest concerns on the mind of Dr. Noubar Afeyan, co-founder and chairman of Moderna, are variants.

As Afeyan rushes to create more doses of the Moderna vaccine to deliver all over the world, he knows that variants are lurking that could require even those vaccinated to get regular boosters.

“The biology of the variants and how they can overcome the biology of how your immune system changes over time, that’s the big unknown,” he said during a visit to South Florida, considered a variant hot spot.

Afeyan says it is more likely than not that even those who are vaccinated will need some form of a booster to make antibodies against variants.

People are projecting this could look like a seasonal flu — and it may — which means annual booster shots of different strains that are being protected against,” he said. “But we don’t know enough to say that for sure.”

In the future, he foresees a booster that would be a combinatio­n of half a dose of the existing vaccine and half a dose of a new variant vaccine.

“What that does is it bolsters your immunity for what you already have and then starts making antibodies for these variants. The combinatio­n might be even better,” he said,

Afeyan, an Armenian-American entreprene­ur, inventor and philanthro­pist, spends his days talking to researcher­s and global leaders and is on the cutting edge of efforts to end the pandemic. He shared his insight on vaccines and the possibilit­y of ending the pandemic.

Vaccines of the future

Moderna anticipate­s cranking out as many as a billion COVID vaccine doses this year. But next year, Moderna could ramp that up to as many as 3 billion doses, Afeyan said.

“We are also testing whether half the amount will still give the same protection,” he said. “In the beginning, we didn’t test that because we wanted to give people the maximum we could, but now we need to reach more people.”

Afeyan said getting the vaccine down to one dose would help

parts of the world where the disease is spreading fast.

“By making more vaccine and making it more potent, suddenly we are doing our part for the rest of the world if we could get it out and let the other government­s do their job,” he said.

Length of immunity from vaccines

Afeyan says how long vaccine immunity will last is hard to know. “I think we’re going to have to watch carefully. We know for up to nine months we can feel confident because that’s when we first did our trials,” he said. “Beyond that, especially with variants, that is a bit of an unknown.”

Moderna is looking into technology that can measure antibody level in people. “We have to be vigilant to see when immunity is waning ... We will see it in cases. If you see a spike in vaccinated people getting infected, we will have to react very quickly. We know what to do about it. We can just vaccinate again.”

On vaccine hesitancy

“At the end of the day, if one wants to work and be in the community, you have to think through the risk you are under and the risk you are putting other people under,” he said.

“It’s clear without this protection, the risk is very high. And as these mutants come about, it’s going to be even higher.

“It’s also clear, based on testing on hundreds of millions of people who have received the vaccine, that it’s effective and reduces the risk dramatical­ly,” he said.

“A vaccine is basically a mask inside your body,” he said. “It’s doing the same thing. It’s preventing the virus, once it gets in, from actually infecting your cells.”

On herd immunity

Afeyan said we may never know the percentage of people who need to be vaccinated or immune to stop the virus from spreading. But he feels hopeful we will know when it happens as cases numbers dwindle.

Refrigerat­ion of vaccines

“We have improved on that front,” he said. “Our product was slated to be kept in the refrigerat­or for 30 days and on the tabletop at room temperatur­e for a whole day. We keep testing to see whether that’s what we should do or if we could go longer. My expectatio­n is that the refrigerat­ion time will be elongated to many months, which means you can ship it to any number of places and it will still be good.”

 ?? MIKE STOCKER / SOUTH FLORIDA SUN SENTINEL ?? Noubar Afeyan, co-founder of the biotechnol­ogy company Moderna, talks with Luisa and Guillermo Jimenez after they received the Moderna COVID-19 vaccine in their car at the Jessie Trice Community Health Center in Miami on Friday.
MIKE STOCKER / SOUTH FLORIDA SUN SENTINEL Noubar Afeyan, co-founder of the biotechnol­ogy company Moderna, talks with Luisa and Guillermo Jimenez after they received the Moderna COVID-19 vaccine in their car at the Jessie Trice Community Health Center in Miami on Friday.

Newspapers in English

Newspapers from United States